Upwards arrow: Go back to top

Join us on LinkedIn for the latest news.

Building Next Generation Companies To Enhance Healthy Lifespan

Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself.

Biotechnology is the solution for a healthier lifespan and reduced healthcare spending.

By investing and thus enabling transformative healthcare companies in their scientific breakthroughs, we will impact human health within the next 10 years.

News & Press

News from our portfolio companies, recent advances in biotech, health tech and investments.

Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic MalignanciesAuron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
29.5.2025
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease PipelineTherini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
14.5.2025
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related DiseasesHAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
8.5.2025
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous LeukemiaAuron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
24.2.2025
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncologyAuron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology
4.2.2025
Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology
Booster Therapeutics launches with $15 M seed financingBooster Therapeutics launches with $15 M seed financing
10.10.2024
Booster Therapeutics launches with $15 M seed financing led by Apollo Health Ventures and Novo Holdings

Investment Strategy

We leverage potential by combining traditional funding with venture building, accomplishing a bigger and more diverse value creation in Europe and the US.

ACTIVE VENTURE CREATION

In our Venture Lab, we partner with scientific experts and turn untapped technologies into transformational companies. This way we acquire founder shares at nominal value– offering unique upsides to our investors.
Scientific & operational expertise
Building top teams
Access to capital & strong syndicates
Risk minimization by conducting killer experiments

Investing in best-in-class companies

Alongside of our venture lab approach, we generate additional value by identifying best-in-class companies at an early stage. Based on breakthrough science and led by amazing founders, we help those companies accelerate.
ACCESS
Access through extensive network and trust due to our deep knowledge
Successful track record since 2017
Accelerate
Leading players in follow on investment rounds
Support by talent and leadership recruitment, guidance on R&D as well as clinical trial and indication selection strategies.

Join us on LinkedIn for the latest news.